FDA/CDC

FDA OKs Medtronic lead for left bundle branch pacing


 

Labeling for a Medtronic pacing lead, already indicated for stimulation of the His bundle, has been expanded to include the left bundle branch (LBB), the company announced on Oct. 17.

The U.S. Food and Drug Administration previously expanded the Medtronic SelectSecure MRI SureScan Model 3830 lead’s approval in 2018 to include His-bundle pacing. “Now this cardiac lead is approved for pacing and sensing at the bundle of His or in the left bundle branch area as an alternative to apical pacing in the right ventricle in a single- or dual-chamber pacing system,” Medtronic states in a press release.

A stamp saying "FDA approved." Olivier Le Moal/Getty Images

The Model 3830 lead was initially approved for atrial or right ventricular pacing and sensing, the announcement says, and now “has more than 20 years of proven performance and reliability.”

The newly expanded conduction system pacing indication is “based on evidence from multiple sources spanning more than 20,000 treated patients,” for which the company cited “Medtronic data on file.”

A version of this article first appeared on Medscape.com.

Recommended Reading

Coffee linked to reduced cardiovascular disease and mortality risk
MDedge Cardiology
Food insecurity a growing problem for many with CVD
MDedge Cardiology
Like texting and driving: The human cost of AI
MDedge Cardiology
Novel head-up CPR position raises odds of survival of out-of-hospital heart attacks
MDedge Cardiology
Athletes with mild HCM can likely continue competitive sports
MDedge Cardiology
ACC calls for more career flexibility in cardiology
MDedge Cardiology
New deep dive into Paxlovid interactions with CVD meds
MDedge Cardiology
AFib detection by smartwatch challenging in some patients
MDedge Cardiology
Apixaban outmatches rivaroxaban in patients with AFib and valvular heart disease
MDedge Cardiology
Diabetes becoming less potent risk factor for CVD events
MDedge Cardiology